Maria L. Ascierto, Ph.D. Saint John's Cancer Institute

Saint John's Cancer Institute's Director of Translational Immunology, Maria L. Ascierto, Ph.D. Contact Dr. Ascierto via email or phone number.

Maria Libera Ascierto on LinkedIn: #aacr19

SITC Annual Meeting Final Program Now Online - Society for

Antoni Ribas – UCLA Graduate Programs in Bioscience (GPB)

Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial - ScienceDirect

Saint John's - The Magazine of Saint John's Health Center - Summer 2022 by Moon Tide Media - Issuu

Immunotherapy Bridge 2021 and Melanoma Bridge 2021: meeting abstracts, Journal of Translational Medicine

Upper Gastrointestinal & Endocrine Tumors - VHIO

Melanoma/Skin Cancer Treatment Center - Santa Monica, CA

Maria ASCIERTO, Post Doctoral Fellow, MS, PhD, Johns Hopkins Medicine, Maryland, JHUSOM, The Sidney Kimmel Comprehensive Cancer Center

Emergence of Small Interfering RNA-Based Gene Drugs for Various Diseases

The immune tumour microenvironment of neuroendocrine tumours and its implications for immune checkpoint inhibitors in: Endocrine-Related Cancer Volume 27 Issue 9 (2020)

Cancers, Free Full-Text

Frontiers Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors

Distant antimetastatic effect of enterotropic colon cancer–derived α4β7+CD8+ T cells

Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma